HIT! High Impact Clinical Trials 3
29 Mar 2026 14:10 15:10
Main Hall
In IgA Nephropathy
| Time | Session |
|---|---|
|
14:10
14:20
|
Opening & Introduction
|
|
14:20
14:32
|
Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)
|
|
14:32
14:35
|
Q&A
|
|
14:35
14:47
|
Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial
|
|
14:47
14:50
|
Q&A
|
|
14:50
15:02
|
Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study
|
|
15:02
15:05
|
Q&A
|
|
15:05
15:10
|
Closing Remarks
|